Johnson & Johnson $JNJ Shares Sold by Talon Private Wealth LLC

Talon Private Wealth LLC lessened its position in Johnson & Johnson (NYSE:JNJ) by 9.8% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,704 shares of the company’s stock after selling 725 shares during the period. Talon Private Wealth LLC’s holdings in Johnson & Johnson were worth $1,112,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Brighton Jones LLC boosted its holdings in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares in the last quarter. Hudson Value Partners LLC lifted its position in shares of Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company’s stock valued at $5,648,000 after acquiring an additional 1,022 shares during the last quarter. Focus Partners Wealth boosted its stake in shares of Johnson & Johnson by 15.6% during the 4th quarter. Focus Partners Wealth now owns 1,033,959 shares of the company’s stock worth $149,531,000 after acquiring an additional 139,500 shares in the last quarter. Graham Capital Management L.P. acquired a new position in shares of Johnson & Johnson in the 4th quarter worth $16,100,000. Finally, Gen Wealth Partners Inc raised its position in shares of Johnson & Johnson by 3.6% during the fourth quarter. Gen Wealth Partners Inc now owns 13,607 shares of the company’s stock worth $1,968,000 after purchasing an additional 468 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on JNJ. Leerink Partnrs cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Citigroup raised their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday, August 21st. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Guggenheim restated a “neutral” rating and issued a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, UBS Group lifted their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $176.29.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

NYSE JNJ opened at $178.20 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market capitalization of $429.15 billion, a price-to-earnings ratio of 19.06, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The company has a 50 day simple moving average of $168.57 and a 200-day simple moving average of $160.78. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the business earned $2.82 EPS. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.